Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase
作者:Xianling Ning、Hailong Qi、Ridong Li、Yunqiao Li、Yan Jin、Michael A. McNutt、Junyi Liu、Yuxin Yin
DOI:10.1016/j.ejmech.2017.06.064
日期:2017.9
targeting of PKM2 therefore has potential as strategy for cancer therapy. Here, we report the synthesis and biologic evaluation of novel naphthoquinone derivatives as selective small molecule inhibitors of PKM2. Some target compounds, such as compound 3k, displayed more potent PKM2 inhibitory activity than the reported optimal PKM2 inhibitor shikonin. The well performing compound 3k also showed nanomolar
丙酮酸激酶M2(PKM2)是在癌细胞中高表达的糖酵解途径的限速酶。癌细胞在很大程度上依赖于PKM2的合成代谢和能量需求,因此,针对PKM2的特异性靶向具有作为癌症治疗策略的潜力。在这里,我们报告新型萘醌衍生物作为PKM2的选择性小分子抑制剂的合成和生物学评估。一些目标化合物(例如化合物3k)比报告的最佳PKM2抑制剂紫草素显示出更强的PKM2抑制活性。性能良好的化合物3k还对具有高表达PKM2的一系列癌细胞系(包括HCT116,Hela和H1299,具有IC 50)具有纳摩尔抗增殖活性。值范围从0.18至1.56μM。此外,化合物3k对癌细胞的细胞毒性比正常细胞高。新型有效的PKM2小分子抑制剂的鉴定不仅为癌症治疗提供了候选化合物,而且还提供了一种工具,可用于深入评估PKM2的功能。